Stay updated on Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the effectiveness or safety evaluation of pembrolizumab followed by radiation therapy in Hodgkin lymphoma patients with relapsed or refractory early stage disease.
    Difference
    0.1%
    Check dated 2024-06-06T14:31:49.000Z thumbnail image
  4. Check
    6 days ago
    No Change Detected
  5. Check
    7 days ago
    No Change Detected
  6. Check
    17 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to provide detailed eligibility criteria for patient enrollment, including specific health conditions and prior treatments required. Previously, this section had no information provided.
    Difference
    46%
    Check dated 2024-05-22T21:12:14.000Z thumbnail image
  7. Check
    39 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:36:29.000Z thumbnail image

Stay in the know with updates to Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab with Radiation in Hodgkin Lymphoma Clinical Trial page.